Role of chemotherapy in breast cancer

References

• Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur. J. Nucl. Med. Mol. Imaging 31(Suppl.1), S149–S161 (2004).
   PubMed Web of Science ®Google Scholar
• Hussain SA, Palmer DH, Moon S, Rea DW. Role of endocrine therapy in metastatic breast cancer. Expert Rev. Anticancer Ther. 4(6), 1179–1195 (2004).
   PubMedGoogle Scholar
• Pusztai L, Symmans FW, Hortobagyi GN. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 12(2), 73–85 (2005).
   PubMedGoogle Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(942), 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet 355, 1757–1770 (2000).
   PubMed Web of Science ®Google Scholar
• Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in 2000 at ages 20–69 years. Lancet 355, 1822 (2000).
   Google Scholar
• Fisher B, Ravdin RG, Ausman RK et al. Surgical adjuvant chemotherapy in cancer of the breast; results of a decade of cooperative investigation. Ann. Surg. 168, 337–356 (1968).
   PubMed Web of Science ®Google Scholar
• Fisher B, Carbone P, Economou SG et al. l-phenylalanine mustard in the management of primary breast cancer: a report of early findings. N. Engl. J. Med. 292, 117–122 (1975).
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 294(8) 405–410 (1976).
   PubMed Web of Science ®Google Scholar
• Carlson RW, Anderson BO, Bensinger W et al. NCCN practice guidelines for breast cancer. Oncology 14, 33–49 (2000).
   PubMedGoogle Scholar
• National Institutes of Health Consensus Development Panel. Conference statement: adjuvant therapy for breast cancer. J. Natl Cancer Inst. 93, 979–989 (2000).
   Google Scholar
• Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: updated international expert consensus of the primary therapy of early breast cancer. J. Clin. Oncol. 21, 3357–3365 (2003).
   PubMed Web of Science ®Google Scholar
• Fumoleau P, Kerbrat P, Romestaing P et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French adjuvant study group 01 trial. J. Clin. Oncol. 21, 298–305 (2003).
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumours: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J. Clin. Oncol. 8, 1483–1496 (1990).
   PubMed Web of Science ®Google Scholar
• Coombes RC, Bliss JM, Wils J et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J. Clin. Oncol. 14, 35–45 (1996).
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Andersen J, Andersson M et al. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc. Am. Soc. Clin. Oncol. 18 (1999) (Abstract 68).
   Google Scholar
• Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 16, 2651–2658, (1998).
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Levine MN, Bramwell VHC et al. A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: update of NCIC CTG MA. 5. Breast Cancer Res. Treat. 76(Suppl 1), S33 (2002).
   Google Scholar
• French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J. Clin. Oncol. 6, 679–688 (1988).
   PubMed Web of Science ®Google Scholar
• The Italian Multicentre Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an italian multicenter trial. J. Clin. Oncol. 6, 976–982 (1988).
   PubMed Web of Science ®Google Scholar
• Poole CJ, Earl HM, Dunn JA et al. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF, Proc. Am. Soc. Clin. Oncol. 22, 4 (2003) (Abstract 13).
   Google Scholar
• French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J. Clin. Oncol. 19, 602–611 (2001).
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Roche H, Kerbrat P et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J. Clin. Oncol. 23(12), 2686–93 (2005).
   PubMed Web of Science ®Google Scholar
• Crown J, O'Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9(Suppl. 2), S24–S32 (2004)
   PubMed Web of Science ®Google Scholar
• Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21, 976–983 (2003).
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Bryant J, Lembersky B et al. paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28 J. Clin. Oncol. 1, 3686–3696 (2005).
   Google Scholar
• Buzdar AU, Singletary SE, Valero V et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin. Cancer Res. 8, 1073–1079 (2002).
   PubMed Web of Science ®Google Scholar
• Jones SE, Savin MA, Asmar L et al. Three-year results of a prospective randomized trial of adjuvant chemotherapy for patients with stage I–III operable, invasive breast cancer comparing four courses of doxorubicin/cyclophosphamide to four courses of docetaxel/cyclophosphamide, Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 59).
   Google Scholar
• Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 352, 2302–2313, (2005).
   PubMed Web of Science ®Google Scholar
• Nowak AK, Wilcken NRC, Stockler MR et al. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncology 5(6), 372–380 (2004).
   Google Scholar
• Roché H, Fumoleau P, Spielmann M et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 versus 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Presented at: San Antonio Breast Cancer Symposium. December 8–11 (2004).
   Google Scholar
• Riou JF, Petitgenet O, Combeau C et al. Cellular uptake and efflux of docetaxel (Taxotere®) and paclitaxel (Taxol®) in P388 cell line. Proc. Am. Assoc. Cancer Res. 35, 385 (1994).
   Google Scholar
• Pegram MD, Slamon DJ. Combination therapy with trastuzumab (herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin. Oncol. 26(4, Suppl. 12), S89–S95 (1999).
   PubMed Web of Science ®Google Scholar
• Romond E. Advances in monoclonal anibodies for breast cancer: joint analysis of NSABP-B-31 and NCCTG-N9831. Proc. Am. Soc. Clin. Oncol. FL, USA (2005).
   Google Scholar
• Piccart-Gebhart M. Advances in monoclonal antibodies for breast cancer: HERA trial. Proc. Am. Soc. Clin. Oncol. FL, USA (2005).
   Google Scholar
• Chan S, Friedrichs K, Noel D et al. 303 Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 17(8), 2341–2354 (1999).
   PubMed Web of Science ®Google Scholar
• Paridaens R, Biganzoli L, Bruning P et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J. Clin. Oncol. 18(4), 724–733 (2000).
   PubMed Web of Science ®Google Scholar
• Fossati R, Confalonieri C, Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J. Clin. Oncol. 16(10), 3439–3460 (1998).
   PubMed Web of Science ®Google Scholar
• Cocconi G. Chemotherapy with and without anthracycline. J. Clin. Oncol. 18(6), 1392–1393 (2000).
   PubMedGoogle Scholar
• Gabizon A, Catane R, Uziely B et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54(4), 987–992 (1994).
   PubMed Web of Science ®Google Scholar
• Holmes FA, Walters RS, Theriault RL et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl Cancer Inst. 83(24), 1797–1805 (1991).
   PubMed Web of Science ®Google Scholar
• Reichman BS, Seidman AD, Crown JP et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol. 11(10), 1943–1951 (1993).
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in study group. J. Clin. Oncol. 17(5), 1413–1424 (1999).
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Spielman M, Guastalla JP et al. Efficacy and safety of docetaxel (Taxotere®) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur. J. Cancer 35(10), 1431–1439 (1999).
   PubMed Web of Science ®Google Scholar
• Bishop JF, Dewar J, Toner GC et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy. J. Clin. Oncol. 17(8), 2355–2364 (1999).
   PubMed Web of Science ®Google Scholar
• Icli E, Akbulut H, Uner A et al. Paclitaxel (T) versus cisplatin plus VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: a phase III randomized study. Turkish Oncology Group. Ann. Oncol. 13(Suppl. 5), S47 (2002).
   PubMed Web of Science ®Google Scholar
• Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin (E1193). J. Clin. Oncol. 21(4), 588–592 (2003).
   PubMed Web of Science ®Google Scholar
• Jones SE, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 23(24), 5542–5551 (2000).
   Google Scholar
• Tabernero J, Climent MA, Lluch A et al. A multicentre, randomized phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann. Oncol. 15(9), 1358–1365 (2004).
   PubMed Web of Science ®Google Scholar
• Seidman AD, Berry D, Cirrincione C et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3-h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J. Clin. Oncol. Proc. Am. Soc. Clin. Oncol.s. 22(14), S512 (2004).
   Google Scholar
• Mackey JR, Paterson A, Dirix LY et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 137 (2002) (Abstract21-35).
   Google Scholar
• Biganzoli L, Cufer T, Bruning P et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J. Clin. Oncol. 20(14), 3114–3121 (2002).
   PubMed Web of Science ®Google Scholar
• Jassem J, Pienkowski T, Pluzanska A et al. Central & Eastern Europe and Israel Pacitaxel Breast Cancer Study Group. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer final results of a randomized Phase III multicenter trial. J. Clin. Oncol. 19(6), 1707–1715 (2001).
   PubMed Web of Science ®Google Scholar
• Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol. 13(11), 2688–2699 (1995).
   PubMed Web of Science ®Google Scholar
• Albain K, Nag S, Calderillo-Ruiz G et al. Global phase III study of gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. Proc. Am. Soc. Clin. Oncol. 22(5) (2004).
   Google Scholar
• Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 34(8), 1274–1281 (1998).
   PubMed Web of Science ®Google Scholar
• Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 17(2), 485–493 (1999).
   PubMed Web of Science ®Google Scholar
• Jones S, Winer E, Vogel C et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J. Clin. Oncol. 13(10), 2567–2574 (1995).
   PubMed Web of Science ®Google Scholar
• Carmichael J, Possinger K, Phillip P et al. Advanced breast cancer: a phase II trial with gemcitabine. J. Clin. Oncol. 13(11), 2731–2736 (1995).
   PubMed Web of Science ®Google Scholar
• Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a Phase II trial. Oncology 62(1), 2–8 (2002).
   PubMed Web of Science ®Google Scholar
• Smorenburg CH, Bontenbal M, Seynaeve C et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res. Treat. 66(1), 83–87 (2001).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N. Engl. J. Med. 344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Pienkowski T, Fumoleau P, Eiermann W et al. Taxotere, cisplatin and herceptin (TCH) in first-line HER-2-positive metastatic breast cancer (MBC) patients, a Phase II pilot study by the Breast Cancer International Research Group (BCIRG)-101. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 2030).
   PubMedGoogle Scholar
• Slamon DJ, Patel R, Northfelt R et al. Phase II pilot study of herceptin combined with taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER-2-neu proto-oncogene a pilot study of the UCLA network. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 193).
   Google Scholar
• Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J. Clin. Oncol. 23(4), 792–799 (2005).
   PubMed Web of Science ®Google Scholar
• Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin. Cancer Res. 4(4), 1013–1019 (1998).
   PubMed Web of Science ®Google Scholar
• Kurosumi M, Tabei T, Suemasu K et al. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast cancinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol. Rep. 7(5), 945–948 (2000).
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in Phase III trial. J. Clin. Oncol. 20(12), 2812–2823 (2002).
   PubMed Web of Science ®Google Scholar
• Buchholz TA, Austin-Seymour MM, Moe RE et al. Effect of delay in radiation in the combined modality treatment of breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 26, 23–35 (1993).
   PubMed Web of Science ®Google Scholar
• Hartsell WF, Recine DC, Griem KL et al. Delaying the initiation of intact breast irradiation for patients with lymph node positive breast cancer increases the risk of local recurrence. Cancer 76, 2497–2503 (1995).
   PubMed Web of Science ®Google Scholar
• Recht A, Come SE, Gelman RS et al. Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early stage, node-positive breast cancer: sequencing, timing and outcome. J. Clin. Oncol. 9, 1662–1667 (1991).
   PubMed Web of Science ®Google Scholar
• Leonard CE, Wood ME, Zhen B et al. Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control? J. Clin. Oncol. 13, 2906–2915 (1995).
   PubMedGoogle Scholar
• Vujovic O, Perera F, Dar AR et al. Does delay in breast irradiation following conservative surgery in node-negative breast cancer patients have an impact on risk of recurrence? Int. J. Radiat. Oncol. Biol. Phys. 40, 869–874 (1998).
   PubMed Web of Science ®Google Scholar
• Buchholz TA, Hunt KK, Amosson CM et al. Sequencing of chemotherapy and radiotherapy in lymph node negative breast cancer. Cancer J. Sci. Am. 5, 159–164 (1999).
   PubMed Web of Science ®Google Scholar
• Mikeljevic JS, Haward R, Johnston C et al. Trends in postoperative radiotherapy delay and effect on survival in breast cancer patients treated with conservation surgery. Br. J. Cancer 90(7), 1343–1348 (2004).
   PubMed Web of Science ®Google Scholar
• Bellon JR, Come SE, Gelman RS et al. Sequencing of chemotherapy and radiation therapy in early stage breast cancer – updated results of a prospective randomized trial. J. Clin. Oncol. 23(9), 1934–1940 (2005).
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Mamounas et al. Sequential methotrexate and fluorouracil for the treatment of node negative breast cancer patients with estrogen receptor negative tumours: eight year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate and fluorouracil. J. Clin. Oncol. 14, 1982–1992 (1996).
   PubMed Web of Science ®Google Scholar
• Overgaard M, Hansen PS, Overgaard J et al. For the Danish Breast Cancer Cooperative Group 82b trial. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N. Engl. J. Med. 337, 949–962 (1997).
   PubMed Web of Science ®Google Scholar
• Ragaz J, Olivotto IA, Spinelli JJ et al. Locoregional radiation therapy in patients with high risk breast cancer receiving adjuvant chemotherapy: 20 year results of the British Columbia randomized trial. J. Natl Cancer Inst. 97(2), 116–126 (2005).
   PubMedGoogle Scholar
• Sartor CI, Peterson BL, Woolf S et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node positive breast cancer: cancer and leukaemia group B 9344. J. Clin. Oncol. 23(1), 30–40 (2005).
   PubMedGoogle Scholar
• Dubey A, Recht A, Come SE et al. Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. Int. J. Radiat. Oncol. Biol. Phys. 45(4), 877–884 (1999).
   PubMedGoogle Scholar
• Lamb D, Atkinson C, Joseph D et al. Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer. Australas. Radiol. 43(2), 220–226 (1999).
   PubMedGoogle Scholar
• Bellon JR, Lindsley KL, Ellis GK et al. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high risk breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 48(2), 393–397 (2000).
   PubMed Web of Science ®Google Scholar
• Ellerbroek N, Martino S, Mautner B et al. Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatment. Breast J. 9(2), 74–78 (2003).
   PubMedGoogle Scholar
• Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J. Clin. Oncol. 21(22), 4165–4174 (2003).
   PubMed Web of Science ®Google Scholar
• Goldstein L, O'Neill A, Sparano J et al. E2197: Phase III AT (doxorubucin/docetaxel) versus AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high-risk node negative breast cancer. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 24).
   Google Scholar
• Gianni L, Baselga J, Eiermann W et al. ECTO Study Group. European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). proc. Am. Soc. Clin. Oncol. (2005) (Abstract 24).
   Google Scholar
• Chan S, Romieu G, Huober J et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 581).
   PubMedGoogle Scholar